bioRxivMicrobiologyPreprint
Data aggregation and mechanistic modeling enable dose-response analysis of SARS-CoV-1 in non-human primates
Philip C. LeeiD, Celine E. SneddeniD, Dylan H. MorrisiD, James O. Lloyd‐SmithiD
Abstract
Dose-response modeling provides estimates of infectious and lethal doses, which can be used to inform control and prevention measures. Unfortunately, data from experimental challenge studies, which are needed to perform dose-response modeling, are often sparse. For example, non-human primate (NHP) challenge studies tend to have small samples sizes and little dose variation, often with only one or two dose levels per study. Thus, it is infeasible to apply traditional dose-response modeling approaches to data from single NHP studies. To address this challenge, we developed a mechanistic Bayesian model that aggregates and analyzes NHP pathogen load data across multiple studies. Our model links dose-infectivity to pathogen kinetics, which allows us to estimate the infectious dose and evaluate dose effects on within-host viral kinetics simultaneously. With this model, we obtained the first-ever ID50 estimate for SARS-CoV-1 in NHPs using data compiled from six NHP challenge studies. Our work demonstrates the value in reusing previous data from animal experiments. Our modeling framework can be applied to other pathogens, enabling robust dose-response inference when individual challenge studies are inconclusive. Author summaryDose-response models are used to estimate pathogen doses needed to cause infection in humans, so they are useful for informing outbreak control policies. Unfortunately, performing dose-response modeling can be difficult due to limitations in the available data. If the pathogen causes significant risk of severe disease or death in humans, then controlled human infections cannot be performed. Additionally, experimental challenge studies of relevant animal models, such as non-human primates (NHPs), often have small sample sizes and limited dose ranges, which make dose-response modeling unfeasible using data from single studies. We developed an approach to aggregate data across multiple challenge studies to enable dose-response modeling in the absence of dose-response experiments. We applied our approach to data from six NHP challenge studies to perform the first-ever dose-response analysis of SARS-CoV-1 in NHPs. Our approach also included a mechanistic, mathematical model of within-host pathogen kinetics, which allowed us to assess the effect of SARS-CoV-1 dosage on patterns of viral RNA shedding. The framework we developed can be readily applied to other host-pathogen systems, and the mechanistic components of our model contribute to a growing movement towards understanding dose effects beyond simple infectivity.
- organism: non-human primate
- research focus: host-pathogen & immune response
- approach: statistical model
- approach: Bayesian inference
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Exposure route drives SARS-CoV-2 infection patterns in non-human primates
Celine E. Snedden, Dylan H. Morris, … James O. Lloyd‐Smith·bioRxiv·Mar 4, 2026
- Establishment of an African green monkey model for COVID-19
C. B. Woolsey, V. Borisevich, … R. W. Cross·bioRxiv·May 17, 2020
- Plasma nirmatrelvir and molnupiravir concentrations required for inhibition of SARS CoV-2 replication differ between rhesus macaques and humans
Ugo Avila-Ponce de León, Shadisadat Esmaeili, … Joshua Tisdell Schiffer·Antimicrobial Agents and ChemotherapyPeer-reviewed·Aug 5, 2026
- Aerosol Exposure of Cynomolgus Macaques to SARS-CoV-2 Results in More Severe Pathology than Existing Models
S. L. Bixler, C. P. Stefan, … M. L. M. Pitt·bioRxiv·Apr 27, 2021
- SARS-CoV-2 infection leads to acute infection with dynamic cellular and inflammatory flux in the lung that varies across nonhuman primate species
D. K. Singh, S. R. Ganatra, … M·bioRxiv·Jun 5, 2020
- Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity reduces lung inflammation
K. K. A. Van Rompay, K. J. Olstad, … J. R. Reader·bioRxiv·Sep 1, 2021